EP3906033A4 - Verfahren und materialien zur erhöhung des transkriptionsfaktor-eb-polypeptid-spiegels - Google Patents
Verfahren und materialien zur erhöhung des transkriptionsfaktor-eb-polypeptid-spiegels Download PDFInfo
- Publication number
- EP3906033A4 EP3906033A4 EP20736104.9A EP20736104A EP3906033A4 EP 3906033 A4 EP3906033 A4 EP 3906033A4 EP 20736104 A EP20736104 A EP 20736104A EP 3906033 A4 EP3906033 A4 EP 3906033A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- materials
- methods
- transcription factor
- polypeptide levels
- increasing transcription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962788049P | 2019-01-03 | 2019-01-03 | |
US201962879374P | 2019-07-26 | 2019-07-26 | |
PCT/US2020/012268 WO2020142748A1 (en) | 2019-01-03 | 2020-01-03 | Methods and materials for increasing transcription factor eb polypeptide levels |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3906033A1 EP3906033A1 (de) | 2021-11-10 |
EP3906033A4 true EP3906033A4 (de) | 2022-11-09 |
Family
ID=71406977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20736104.9A Pending EP3906033A4 (de) | 2019-01-03 | 2020-01-03 | Verfahren und materialien zur erhöhung des transkriptionsfaktor-eb-polypeptid-spiegels |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220112218A1 (de) |
EP (1) | EP3906033A4 (de) |
JP (1) | JP7566753B2 (de) |
KR (1) | KR20210111787A (de) |
CN (1) | CN113316453A (de) |
AU (1) | AU2020204717A1 (de) |
BR (1) | BR112021012950A2 (de) |
CA (1) | CA3123902A1 (de) |
IL (1) | IL284403A (de) |
MX (1) | MX2021008152A (de) |
SG (1) | SG11202105685TA (de) |
WO (1) | WO2020142748A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
CZ309449B6 (cs) * | 2020-12-24 | 2023-01-25 | Ústav experimentální botaniky AV ČR, v. v. i. | Chinazolinové deriváty jako selektivní inhibitory cyklooxygenázy-1 |
CN113248518B (zh) * | 2021-06-21 | 2022-03-25 | 山东大学 | 嘧啶哌嗪类衍生物及其制备方法与应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030078166A1 (en) * | 2000-09-15 | 2003-04-24 | Robert Davies | Pyrazole compounds useful as protein kinase inhibitors |
WO2003057695A1 (en) * | 2001-12-21 | 2003-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,6 naphthyridines useful as inhibitors of syk kinase |
WO2004037814A1 (en) * | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
WO2004101513A2 (en) * | 2003-05-08 | 2004-11-25 | E.I. Dupont De Nemours And Company | Preparation of (e)- and (z)-2-methyl-2-butenoic acids |
WO2010015518A2 (de) * | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim Interntional Gmbh | 4-dimethylamino-phenyl-substituierte naphthyridine und ihre verwendung als arzneimittel |
WO2010015520A1 (de) * | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Substituierte naphthyridine und ihre verwendung als arzneimittel |
WO2011134971A1 (en) * | 2010-04-29 | 2011-11-03 | Glaxo Group Limited | 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors |
WO2016081365A1 (en) * | 2014-11-19 | 2016-05-26 | Rush University Medical Center | Compositions and methods for treating lysosomal disorders |
WO2018089499A1 (en) * | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF |
WO2018089433A1 (en) * | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
WO2018089493A1 (en) * | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PYRROLE mTORC INHIBITORS AND USES THEREOF |
WO2018191146A1 (en) * | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
JP2005503425A (ja) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
WO2004101512A2 (en) | 2003-05-13 | 2004-11-25 | Smithkline Beecham Corporation | Naphthyridine integrase inhibitors |
WO2008157500A1 (en) * | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
-
2020
- 2020-01-03 CN CN202080007921.4A patent/CN113316453A/zh active Pending
- 2020-01-03 AU AU2020204717A patent/AU2020204717A1/en active Pending
- 2020-01-03 EP EP20736104.9A patent/EP3906033A4/de active Pending
- 2020-01-03 BR BR112021012950-2A patent/BR112021012950A2/pt unknown
- 2020-01-03 MX MX2021008152A patent/MX2021008152A/es unknown
- 2020-01-03 SG SG11202105685TA patent/SG11202105685TA/en unknown
- 2020-01-03 CA CA3123902A patent/CA3123902A1/en active Pending
- 2020-01-03 JP JP2021538743A patent/JP7566753B2/ja active Active
- 2020-01-03 WO PCT/US2020/012268 patent/WO2020142748A1/en unknown
- 2020-01-03 US US17/420,597 patent/US20220112218A1/en active Pending
- 2020-01-03 KR KR1020217022772A patent/KR20210111787A/ko unknown
-
2021
- 2021-06-27 IL IL284403A patent/IL284403A/en unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030078166A1 (en) * | 2000-09-15 | 2003-04-24 | Robert Davies | Pyrazole compounds useful as protein kinase inhibitors |
WO2003057695A1 (en) * | 2001-12-21 | 2003-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,6 naphthyridines useful as inhibitors of syk kinase |
WO2004037814A1 (en) * | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
WO2004101513A2 (en) * | 2003-05-08 | 2004-11-25 | E.I. Dupont De Nemours And Company | Preparation of (e)- and (z)-2-methyl-2-butenoic acids |
WO2010015518A2 (de) * | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim Interntional Gmbh | 4-dimethylamino-phenyl-substituierte naphthyridine und ihre verwendung als arzneimittel |
WO2010015520A1 (de) * | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Substituierte naphthyridine und ihre verwendung als arzneimittel |
WO2011134971A1 (en) * | 2010-04-29 | 2011-11-03 | Glaxo Group Limited | 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors |
WO2016081365A1 (en) * | 2014-11-19 | 2016-05-26 | Rush University Medical Center | Compositions and methods for treating lysosomal disorders |
WO2018089499A1 (en) * | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF |
WO2018089433A1 (en) * | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
WO2018089493A1 (en) * | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PYRROLE mTORC INHIBITORS AND USES THEREOF |
WO2018191146A1 (en) * | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
Non-Patent Citations (2)
Title |
---|
JOHNS B A ET AL: "1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 19, no. 6, 15 March 2009 (2009-03-15), pages 1807 - 1810, XP026005884, ISSN: 0960-894X, [retrieved on 20090130], DOI: 10.1016/J.BMCL.2009.01.089 * |
JOHNS B A ET AL: "The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 19, no. 6, 15 March 2009 (2009-03-15), pages 1802 - 1806, XP026005883, ISSN: 0960-894X, [retrieved on 20090130], DOI: 10.1016/J.BMCL.2009.01.090 * |
Also Published As
Publication number | Publication date |
---|---|
CN113316453A (zh) | 2021-08-27 |
WO2020142748A1 (en) | 2020-07-09 |
IL284403A (en) | 2021-08-31 |
MX2021008152A (es) | 2021-10-13 |
JP7566753B2 (ja) | 2024-10-15 |
CA3123902A1 (en) | 2020-07-09 |
EP3906033A1 (de) | 2021-11-10 |
BR112021012950A2 (pt) | 2021-09-14 |
KR20210111787A (ko) | 2021-09-13 |
SG11202105685TA (en) | 2021-06-29 |
US20220112218A1 (en) | 2022-04-14 |
AU2020204717A1 (en) | 2021-06-10 |
JP2022516631A (ja) | 2022-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL284403A (en) | Methods and materials for increasing EB transcription factor polypeptide levels | |
EP3839034A4 (de) | Kulturmaterial und verwendung desselben | |
EP4021928A4 (de) | Modifiziertes n-810 und verfahren dafür | |
EP4006054A4 (de) | Verfahren und zusammensetzung für anti-cd73-antikörper und varianten | |
EP4009777A4 (de) | Transkriptionsfaktor nterf221 und verfahren zur verwendung davon | |
EP4026382A4 (de) | Verfahren und vorrichtungen für sidelink-vorgänge | |
EP3976657A4 (de) | Anti-trka-antikörper und verwendungen davon | |
EP3980004A4 (de) | Tributyrinzusammensetzungen und verfahren dafür | |
EP3971225A4 (de) | Polymerisierbare zusammensetzung für optisches material und verwendung davon | |
EP4049008A4 (de) | Verfahren zum nachweis von fentanylanaloga und kits dafür | |
EP4069849A4 (de) | Leberspezifischer promotor und verwendung davon | |
EP4081645A4 (de) | Fermentationsverfahren und verwendungen davon | |
EP4007586A4 (de) | Zellen zur verbesserten immuntherapie und deren verwendungen | |
EP3960731A4 (de) | Thiolhaltige zusammensetzung für optisches material und polymerisierbare zusammensetzung für optisches material | |
EP4025585A4 (de) | Modifizierte peptide und damit verbundene verwendungsverfahren | |
EP3605840A4 (de) | Betriebsverstärker und steuerverfahren dafür | |
EP4007591A4 (de) | Materialien und verfahren zum multidirektionalen biotransport | |
EP4023663A4 (de) | Polypeptid und seine verwendung | |
EP3965796A4 (de) | Verfahren und materialien zur behandlung von herz-kreislauf-erkrankungen | |
EP4031565A4 (de) | Immuntherapieverbindungen und -verfahren | |
AU2020327592A1 (en) | Sprayable composition and method | |
EP3927828A4 (de) | Antikörper und enonomere | |
EP3957724A4 (de) | Transaminase-mutant und verwendung davon | |
EP3933566A4 (de) | Digitale vorrichtung und steuerungsverfahren dafür | |
EP3878953A4 (de) | Monooxygenasemutant und anwendung davon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210803 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40061391 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220907 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/00 20060101ALI20220901BHEP Ipc: A61K 31/517 20060101ALI20220901BHEP Ipc: A61K 31/519 20060101ALI20220901BHEP Ipc: C07D 519/00 20060101ALI20220901BHEP Ipc: C07D 239/94 20060101ALI20220901BHEP Ipc: C07D 471/04 20060101ALI20220901BHEP Ipc: C07D 417/14 20060101ALI20220901BHEP Ipc: C07D 413/14 20060101ALI20220901BHEP Ipc: C07D 405/14 20060101ALI20220901BHEP Ipc: C07D 403/14 20060101ALI20220901BHEP Ipc: C07D 401/14 20060101ALI20220901BHEP Ipc: C07D 401/04 20060101AFI20220901BHEP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031519000 Ipc: C07D0401040000 |
|
DA4 | Supplementary search report drawn up and despatched (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/00 20060101ALI20220929BHEP Ipc: A61K 31/517 20060101ALI20220929BHEP Ipc: A61K 31/519 20060101ALI20220929BHEP Ipc: C07D 519/00 20060101ALI20220929BHEP Ipc: C07D 239/94 20060101ALI20220929BHEP Ipc: C07D 471/04 20060101ALI20220929BHEP Ipc: C07D 417/14 20060101ALI20220929BHEP Ipc: C07D 413/14 20060101ALI20220929BHEP Ipc: C07D 405/14 20060101ALI20220929BHEP Ipc: C07D 403/14 20060101ALI20220929BHEP Ipc: C07D 401/14 20060101ALI20220929BHEP Ipc: C07D 401/04 20060101AFI20220929BHEP |
|
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20221012 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/00 20060101ALI20221006BHEP Ipc: A61K 31/517 20060101ALI20221006BHEP Ipc: A61K 31/519 20060101ALI20221006BHEP Ipc: C07D 519/00 20060101ALI20221006BHEP Ipc: C07D 239/94 20060101ALI20221006BHEP Ipc: C07D 471/04 20060101ALI20221006BHEP Ipc: C07D 417/14 20060101ALI20221006BHEP Ipc: C07D 413/14 20060101ALI20221006BHEP Ipc: C07D 405/14 20060101ALI20221006BHEP Ipc: C07D 403/14 20060101ALI20221006BHEP Ipc: C07D 401/14 20060101ALI20221006BHEP Ipc: C07D 401/04 20060101AFI20221006BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230925 |